Current Report Filing (8-k)
07 March 2017 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 2, 2017
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-35068
|
|
41-2193603
|
(State of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
351 Galveston Drive
Redwood City, CA 94063
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:
(650) 216-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On March 2, 2017, AcelRx Pharmaceuticals, Inc., or the Company, conducted a conference call during which members of its senior management team provided a business update and discussed financial results for the quarter and year ended December 31, 2016 and certain other information. A copy of the transcript of the conference call is attached as Exhibit 99.1 to this Report.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Transcript of AcelRx Pharmaceuticals, Inc. Fourth Quarter 2016 Financial Results Conference Call on March 2, 2017, at 4:30 p.m. ET.
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 6, 2017
|
ACELRX PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Jane Wright-Mitchell
|
|
|
|
Jane Wright-Mitchell
|
|
|
|
Chief Legal Officer
|
|
INDEX TO EXHIBITS
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Transcript of AcelRx Pharmaceuticals, Inc. Fourth Quarter 2016 Financial Results Conference Call on March 2, 2017, at 4:30 p.m. ET.
|
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Aug 2023 to Aug 2024